Sucampo Pharmaceuticals aims to grow Amitiza line — 4 key notes

Eric Oliver - Print  |

Sucampo Pharmaceuticals is focusing its efforts on growing its Amitiza digestive disease line, Zacks reports.

Here's what you should know:

1. Sucampo's Amitiza is the company's only marketed product to date. Mylan markets the product in Japan, while Takeda holds global marketing rights to Amitiza. Takeda is working on launching Amitiza globally.

2. Sucampo is attempting to earn FDA approval for adult and pediatric patients by the second half of 2017.

3. Zacks reports the pharmaceutical company is attempting to make several acquisitions, as well. Sucampo recently acquired R-Tech, adding Rescula to its market drug list. In acquiring R-Tech, Sucampo added service lines in gastroenterology, ophthalmology, autoimmune disease, inflammatory diseases and oncology.

4. Sucampo also added a late stage Niemann-Pick Disease treatment to its development pipeline.

More articles on gastroenterology: 
AGA on Better Care Reconciliation Act: 'Patient access to care in peril'
GI center to know: University Gastroenterology
Takeda's CEO under pressure & more — 5 GI company key notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.